<DOC>
	<DOCNO>NCT00519870</DOCNO>
	<brief_summary>In addition effective vasodilator , angiotensin-converting enzyme inhibitor ( ACEIs ) angiotensin receptor blocker ( ARBs ) exert neurohumoral inhibitory action , inhibition vascular remodel smooth muscle cell proliferation amelioration endothelial dysfunction . These beneficial effect , render agent appropriate use treatment pulmonary hypertension . However , data regard use ACEIs ARBs treatment PHT limit . In study , efficacy ARB , losartan compare calcium channel blocker , nifedipine treatment pulmonary hypertension use echocardiographic , 6-minute walk test ( 6MWT ) , cardiopulmonary exercise test , endothelin-1 levels.Losartan effective nifedipine reduce Doppler echocardiographically measure PAP improve exercise capacity 6MWT CPET . However short-term use losartan nifedipine statistically significant effect endothelin-1 level patient PHT .</brief_summary>
	<brief_title>Losartan Therapy Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Pulmonary hypertension diagnose Doppler echocardiographic examination ( mean pulmonary artery pressure &gt; 26mmHg ) acute infectious inflammatory disease , exacerbation chronic obstructive pulmonary disease , malignancy , acute coronary syndrome last 4 week , uncontrolled arrhythmia hypertension , decompensated heart failure , acute pulmonary embolus , thrombus low extremity , oxygen saturation 85 % rest , failure cooperate CPET</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Angiotensin receptor blocker</keyword>
	<keyword>Calcium channel blocker</keyword>
</DOC>